Iovance (IOVA) Soars 33%, Hits All-Time High

Group 1 - Iovance Biotherapeutics Inc. (NASDAQ:IOVA) saw a significant increase in its stock price, rising by 32.9% week-on-week to reach an all-time high after UBS raised its price target from $2 to $4 while maintaining a "neutral" stance [1][3] - The company is set to participate in Barclays' 28th Annual Global Healthcare Conference on March 11, where investors are expected to look for developments that could influence buying interest [2] - Iovance reported a net loss of $390.98 million for the last year, which is a 5% increase from the previous year's loss of $372 million, while total revenues increased by 60.6% to $263.5 million from $164.07 million year-on-year [3] Group 2 - In the fourth quarter, Iovance's net loss narrowed by 8% to $71.9 million compared to $78.5 million in the same period the previous year, with revenues increasing by 17.6% to $86.7 million from $73.69 million year-on-year [3]